#APVO451
$APVO — Other Company Update

Aptevo Therapeutics announced progress in its next-generation trispecific programs, focusing on optimizing candidates for scalable manufacturing ahead of future human testing. The lead candidate, APVO451, is expected to enter IND-enabling studies in 1H...

🧵 continued ↓
September 24, 2026 at 7:17 PM
🚀 Zacks Small Cap Research - APVO: Focusing on Three Key Areas of Development
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-apvo-focusing-on-three-key-areas-of-development/
#AptevoTh
e#AptevoTherapeuticsp#APVOi#Mipletamig##RAINIER##APVO451##Nectin4d#PDL1r#Radiopharmaceu
August 24, 2026 at 5:05 PM
🚀 Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
🔎 Read the full update:
➡️https://theminingnews.com/aptevo-secures-1-5-million-non-dilutive-research-grant-from-the-andy
June 30, 2026 at 12:08 PM
#APVO Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

https://www.stocktitan.net/news/APVO/aptevo-provides-2q26-business-update-and-reports-second-quarter-3wmp5ms89uo1.html
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Aptevo Therapeutics (NASDAQ: APVO) reported its 2Q26 business update, emphasizing clinical progress of lead candidate mipletamig in frontline acute myeloid leukemia (AML), non-dilutive funding for trispecific candidate APVO451, and expansion into radiopharmaceuticals through a 50/50 collaboration with Niowave.In the Phase 1b/2 RAINIER trial, mipletamig plus venetoclax and azacitidine showed an 87% clinical benefit rate and 81% remission rate across 31 evaluable unfit frontline AML patients, with 55% of CR/CRi patients reaching MRD-negative status and six patients proceeding to allogeneic transplant. Aptevo received a $1.5 million non-dilutive grant to support APVO451 IND-enabling work and targets development candidate selection by year-end 2026. The Niowave collaboration covers up to three radiopharmaceutical programs and includes an equity investment giving Niowave an initial 7.9% ownership, potentially rising to 19.99%. Aptevo reported $9.8 million in cash and cash equivalents as of June 30, 2026, and raised $0.6 million via its SEPA facility during the quarter.
www.stocktitan.net
August 14, 2026 at 12:05 PM
#APVO Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

https://www.stocktitan.net/news/APVO/aptevo-secures-1-5-million-non-dilutive-research-grant-from-the-andy-5mn247kc2vok.html
Aptevo gets $1.5M grant to advance a trispecific cancer drug
The CARE Fund grant supports APVO451 IND-enabling work, with development candidate selection targeted by year-end 2026 and IND studies in Q1 2027.
www.stocktitan.net
June 30, 2026 at 12:05 PM
#APVO Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

https://www.stocktitan.net/news/APVO/aptevo-unveils-two-next-generation-industry-leading-trispecifics-am9bmlisr2q2.html
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
Aptevo Therapeutics (NASDAQ:APVO) has expanded its oncology pipeline with two new trispecific candidates, APVO452 and APVO451, targeting prostate cancer and multiple solid tumors. These therapeutics leverage the company's proprietary ADAPTIR-FLEX platform and build upon clinical validation from mipletamig, their lead CD3-directed candidate.APVO452 targets PSMA, CD3, and CD40 for prostate cancers, while APVO451 targets Nectin-4, CD3, and CD40 for various solid tumors. Both therapeutics are designed to simultaneously engage tumor antigens, activate T cells, and modulate immunosuppressive cells in the tumor microenvironment.This expansion brings Aptevo's pipeline to eight bispecific and trispecific candidates, including five molecules utilizing their CRIS-7-derived CD3 pathway, positioning them as a leader in next-generation T cell engagers for both hematologic and solid tumor cancers.
www.stocktitan.net
September 4, 2025 at 12:45 PM